Table 1.
Capture efficiency in spike experiments in whole blood samples from a normal volunteer.
| Nanocarriers against antibody | Cell line | Capture yield (%) |
|---|---|---|
| EGFRa | A-431 (skin) | 79 ± 8 |
| EGFR+EpCAMb | A-431 | 93 ± 2 |
| HER2c | SK-BR-3 (breast) | 69 ± 7 |
| HER2+EpCAM | SK-BR-3 | 93 ± 10 |
| EpCAM | COLO 205 (colon) | 75 ± 9 |
| CKd | COLO 205 | 79 ± 6 |
| EpCAM | BT-20 (breast) | 45 ± 8 |
| EpCAM+MUC1e | BT-20 | 78 ± 10 |
a
anti-Epidermal Growth Factor Receptor 1,
b
anti-Epithelial Cell Adhesion Molecule,
c
anti-Epidermal Growth Factor Receptor 2,
d
anti-Cytokeratin, and
e
anti-Mucin 1.